Breast cancer racial disparities: Unanswered questions

Cancer Research

Volumn 71, Issue 3, 2011, Pages 640-644

  Ademuyiwa, Foluso O ^a   Edge, Stephen B ^a   Erwin, Deborah O ^a   Orom, Heather ^b   Ambrosone, Christine B ^a   Underwood III, Willie ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COMORBIDITY; DRUG TOLERANCE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; MEDICARE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; PROGNOSIS; UNITED STATES;

EID: 79551531779     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3021     Document Type: Review

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. CA Cancer J Clin 2010;60:277-300.
2. Reis LAG, Eisner MP, Kosary CL. SEER Cancer Statistics Review 1973-1998. Bethseda, MD. National Cancer Institute; 2001.
3. Gray GE, Henderson BE, Pike MC. Changing ratio of breast cancer incidence rates with age of black females compared with white females in the United States. J Natl Cancer Inst 1980;64:461-3.
4. Marbella AM, Layde PM. Racial trends in age-specific breast cancer mortality rates in US women. Am J Public Health 2001;91:118-21.
5. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2007.
6. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-35.
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-8.
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
9. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70.
10. Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 1996;77:1465-71.
11. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
12. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
13. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009;11:R31.
14. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010;116:4933-43.
15. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L. Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst 2003;95:478-83.
16. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169:626-32.
17. Zinser GM, Suckow M, Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J Steroid Biochem Mol Biol 2005;97:153-64.
18. Pendas-Franco N, González-Sancho JM, Suárez Y, Aguilera O, Steinmeyer A, Gamallo C, et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007;75:193-207.
19. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757-63.
20. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-21.
21. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of highrisk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005;294:1925-33.
22. Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000;107:186-91.
23. John EM, Miron A, Gong G, Phipps Al, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-76.
24. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
25. Fejerman L, Haiman CA, Reich D, Tandon A, Deo RC, John EM, et al. An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:3110-7.
26. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009;27:4515-21.
27. Ademuyiwa F, Neuhausen S, Adebamowo C, Ogundiran T, Rotimi C, Colilla S, et al. Early Onset Breast Cancer in Black Women of African ancestry: Genetic or Environmental Influence? Anaheim, CA: American Association for Cancer Research; 2005.
28. Pearlman DN, Rakowski W, Ehrich B, Clark MA. Breast cancer screening practices among black, Hispanic, and white women: reassessing differences. Am J Prev Med 1996;12:327-37.
29. O'Malley MS, Earp JA, Hawley ST, Schell MJ, Mathews HF, Mitchell J. The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening? Am J Public Health 2001;91:49-54.
30. Mandelblatt JS, Gold K, O'Malley AS, Taylor K, Cagney K, Hopkins JS, et al. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med 1999;28:418-25.
31. Rakowski W, Clark MA, Rogers ML, Weitzen S. Investigating reversals of association for utilization of recent mammography among Hispanic and non-Hispanic Black women. Cancer Causes Control 2009;20:1483-95.
32. Johnson ET. Breast cancer racial differences before age 40-implications for screening. J Natl Med Assoc 2002;94:149-56.
33. Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?Med Care 2009;47:765-73.
34. Mandelblatt JS, Kerner JF, Hadley J, Hwang YT, Eggert L, Johnson LE, et al. Variations in breast carcinoma treatment in older Medicare beneficiaries: is it black or white. Cancer 2002;95:1401-14.
35. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 2003;81:21-31.
36. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 2006;99:313-21.
37. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24:4888-94.
38. Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol 2010;28:4135-41.
39. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984-92.
40. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006;24:1357-62.
41. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-6.
42. Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc 1996;88:630-4.
43. Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995;87:1747-59.
44. Haggstrom DA, Quale C, Smith-Bindman R. Differences in the quality of breast cancer care among vulnerable populations. Cancer 2005;104:2347-58.